Navigation Links
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
Date:4/30/2009

BONITA SPRINGS, Fla., April 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced that preclinical data were presented on its novel molecule, AFP-464, during the recent AACR 100th Annual Meeting 2009 in Denver. "This research represents a significant advancement in the treatment of Triple Negative Breast Cancer, one of the most aggressive forms of invasive breast cancer," stated Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris.

Sponsored by Tigris, the research was led by Angelika Burger, Ph.D., director of the Translational Research Laboratory at the Barbara Ann Karmanos Cancer Institute and professor of Pharmacology at Wayne State University School of Medicine in Detroit. The research found that the luminal (ER-positive) and the triple negative (ER, PR, and HER-2 negative) breast cancer cell lines with the basal A gene profile subtype were very sensitive to AFP-464, while the triple negative cell lines with the basal B subtype were not. However, when the latter was pre-treated with a histone deacetylase inhibitor, such as the suberoylanilide hydroxamic acid (SAHA), also known as vorinostat (Zolinza(R), Merck & Co. Inc.), the cells became very sensitive to AFP-464. The mechanism in which this is achieved is believed to be the de-silencing of ER expression by the histone deacetylase inhibitor, followed by CYP1A1 induction and subsequent AFP metabolism into active species that covalently bind to DNA in these cancer cells and cause specific cell death.

Dr. Burger said the findings offer particular hope to those women battling triple-negative breast cancer. "We could now find a way to treat every kind of invasive, metastatic breast cancer, the ER-positive and ER-negative types with AFP-464," said Dr. Burger. "The synergism between AFP-464 and vorinostat in the triple negative breast cancer cell lines is very impressive."

'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
2. Tigris Pharmaceuticals Files IND Application for GGTI-2418
3. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
4. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
7. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
8. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
9. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
10. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DUBLIN , September 19, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the ... Pre-packed Chromatography Columns"  report to their offering.  ... columns market is one of the fastest-growing segments ... at $1.2 billion in 2013, and expected to ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Bipartisan passage ... a bill designed to stimulate development and commercialization of ... being praised by leaders of SPIE, the international ... Revitalizing American Manufacturing and Innovation (RAMI) Act, now moves ... authors have said they are optimistic that it will ...
(Date:9/18/2014)... 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research ... and "2014 Deep Research Report on Global and ... database. Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... Global and China Acetic Acid Industry" is a ... China and Global Acetic Acid Market. ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... At the Boston Atrial,Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: ... remote magnetic ablation that it believes will enhance ... Navigation,System. In booth #917, Stereotaxis will exhibit ... Cardiodrive(R) System for enhanced remote,catheter control and improved ...
... 14 In meetings held in association,with the JP ... (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and ... approvals in 2009 in,addition to potential label expansion for ... Spectrum Pharmaceuticals, Inc.,(Spectrum) for Zevalin. , ...
... At the end of December,Trinitas Comprehensive Cancer Center ... state of New Jersey to offer cancer patients treatment ... VAR ).,RapidArc is a fast, precise form of ... is possible with conventional radiation therapy,technologies. By delivering ...
Cached Biology Technology:Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 2Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 3
(Date:9/18/2014)... novel robotic system that can operate inside the bore ... part of a biomedical research partnership program at Brigham ... determining if the robot, in conjunction with real-time MRI ... less costly, and less discomforting for the patient. The ... cancer therapies with greater precision. , Developed by a ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
(Date:9/18/2014)... generally seem to be cheerful, happy-go-lucky characters, so you ... on life. , In fact some dogs are ... of Sydney shows. , "This research is exciting ... dogs objectively and non-invasively. It offers researchers and dog ... how that changes," said Dr Melissa Starling, from the ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... fossil fuel air pollution in the United States by ... , This novel way to measure carbon dioxide produced ... atmospheric scientists better understand where pollution is located and ... fossil-fuel-emitted carbon dioxide will be important as countries throughout ...
... used to help steady buildings against earthquakes, according to ... loose, sandy soil into rock. , When a major ... with disastrous consequences for buildings sitting on them. Currently, ... bind loose grains together. But these epoxy chemicals may ...
... Friedreich's ataxia is one of those diseases few have heard ... individual -- usually a child or teenager -- it is ... arms and legs, vision impairment and slurred speech, but eventually ... to heart failure later in life. There is no cure ...
Cached Biology News:Scientists map air pollution using corn grown in US fields 2Moonlighting enzyme linked to neurodegenerative disease 2Moonlighting enzyme linked to neurodegenerative disease 3
... The SPD101B is a no-frills, basic SpeedVac ... Although economically priced, this unit still features ... a digitial display of time and heat. ... samples and accepts a wide variety of ...
... Jouan RC Maxi MB (for aqueous, other ... concentrator/centrifugal evaporator systems respond to specific applications ... and safe concentration of heat-labile samples. The ... different of cold traps and a wide ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
...
Biology Products: